A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
Completed · Phase 2 · Has a placebo group
Conditions studied: Arthritis, Rheumatoid
In brief
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. One out of seven will receive adalimumab (Humira®) and one out of seven will only receive inactive substances (placebo.)
Key facts
- Study ID
- NCT00550446
- Run by
- Pfizer
- People needed
- 386
- Starts
- 2007-09-01
- Expected to finish
- 2009-01-01
- Last updated by the study team
- 2013-01-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subjects must have active rheumatoid arthritis
- Subjects must have failed at least 1 disease modifying anti-rheumatic drug (DMARD)
- Subjects must not be currently taking any DMARD other than an antimalarial
You may not qualify if…
- Subjects who discontinued any previous TNF inhibitor therapy for either lack of benefit or safety.
- Subjects who previously received adalimumab (Humira®) therapy for any reason.
- Subjects with evidence of blood disorders, chronic infections or untreated tuberculosis
Where it is running
- Pfizer Investigational Site — Little Rock, Arkansas, United States
- Pfizer Investigational Site — Northridge, California, United States
- Pfizer Investigational Site — Palo Alto, California, United States
- Pfizer Investigational Site — Stanford, California, United States
- Pfizer Investigational Site — Tarzana, California, United States
- Pfizer Investigational Site — Upland, California, United States
- Pfizer Investigational Site — Orlando, Florida, United States
- Pfizer Investigational Site — Tampa, Florida, United States
- Pfizer Investigational Site — Morton Grove, Illinois, United States
- Pfizer Investigational Site — Rockford, Illinois, United States
- Pfizer Investigational Site — Cedar Rapids, Iowa, United States
- Pfizer Investigational Site — Wichita, Kansas, United States
- Pfizer Investigational Site — Wichita, Kansas, United States
- Pfizer Investigational Site — New Orleans, Louisiana, United States
- Pfizer Investigational Site — Hickory, North Carolina, United States
- Pfizer Investigational Site — Hickory, North Carolina, United States
- Pfizer Investigational Site — Dayton, Ohio, United States
- Pfizer Investigational Site — Duncansville, Pennsylvania, United States
- Pfizer Investigational Site — Knoxville, Tennessee, United States
- Pfizer Investigational Site — Dallas, Texas, United States
- Pfizer Investigational Site — Mesquite, Texas, United States
- Pfizer Investigational Site — Porto Alegre, Rio Grande do Sul, Brazil
- Pfizer Investigational Site — São Paulo, São Paulo, Brazil
- Pfizer Investigational Site — Pleven, Bulgaria
- Pfizer Investigational Site — Mesa, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.